Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

The conversation is about the availability of WINLEVI, a hair loss treatment, and the possibility of getting it compounded. The user is seeking information on when they can obtain the treatment.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

A user has had great results with a spray containing 6% minoxidil, 0.03% finasteride, and 0.25% tretinoin from Roman but is seeking cheaper alternatives with the same ingredients. They are looking for suggestions for more affordable sites or pharmacies.

User wants to add RCP to regimen and asks if it can be applied with topical minoxidil and/or finasteride at night.

The user is struggling with seborrheic dermatitis and plans to try ciclopirox olamine after finding ketoconazole too drying. They are also using finasteride daily.

Availability of topical anti-androgens, especially RU58841, in Australia. Issues with customs seizures and lack of credible local sources.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Hmi115, a prolactin receptor blocker, showed promise for hair growth, but results from Phase 2 trials have not been published. ABS-201, an AI-based analog, is expected to begin trials in December 2025, while commercialization of treatments like PP-405 is anticipated around 2027.

Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.

The user noticed increased hair fullness after using a minoxidil and finasteride oral capsule but is unsure if the 1.25 mg minoxidil dose is sufficient. They are considering switching to a higher dose and are waiting for a dermatologist's advice.

The conversation discusses whether a product recommended by a Portuguese pharmacist is the same as Minoxidil. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

Anagenica.com has poor customer service but delivers quality hair loss products like liposomal dutasteride. OP recommends ordering directly from Farmacia Tristiana for better service.

Setipiprant and Fevipiprant are questioned for their effectiveness in hair maintenance, with skepticism due to lack of convincing results beyond vellus hair growth. The user is satisfied with Minoxidil and Finasteride but is curious about the potential of DP2 inhibitors.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

User's 2-month progress with hair loss treatment includes Ket 3x a week, Min 2x a day, Dut 0.5 every other day, Vit D 125mcg daily, and PRP once a month. Users discuss treatment effectiveness, side effects, and alternative solutions.

The user mixed Pyrilutamide with a KB solution and noticed some undissolved powder, questioning if more shaking or liquid is needed. They use Pyrilutamide from Anagenic.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

A 16 year old's experience with using pyrilutamide to treat hair loss, and the potential side effects of adding tretinoin to minoxidil and finasteride treatments.

A user seeks advice on mixing RU58841 serum using European ingredients, specifically struggling to find propylene glycol. They are looking for alternatives to American products commonly recommended in guides.

The conversation discusses the difference between the commercially available Pyrilutamide and the version in clinical trials. It also mentions treatments like Minoxidil, finasteride, and RU58841 for hair loss.

The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.

The conversation discusses the effectiveness and safety of hair loss treatments, specifically RU58841 and Pyrilutimide (Pyril), with users sharing that Pyril was no more effective than a placebo and expressing concerns about the safety of RU58841 based on personal experiences and the lack of pharmaceutical interest.

The conversation discusses using Latanoprost for hair regrowth, with the original poster seeking advice on where to purchase it without a prescription. Users suggest alternatives like Triple Hair's TH-07, which includes Finasteride, Minoxidil, and Latanoprost, and Strut's Latanoprost with melatonin and caffeine.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Pelage Pharmaceuticals' PP405, a new hair loss treatment, was recognized by Time Magazine as one of the best inventions of 2025. The conversation expresses optimism about the recognition of this in-development treatment.